Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

Trial Details

NCT ID
NCT04585490
Phase
PHASE3
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Durvalumab
  • Carboplatin
  • Pemetrexed
  • Paclitaxel
  • Cisplatin
  • AVENIO ctDNA Surveillance Kit
Locations (sample)
  • Stanford, California, United States|37.42411,-122.16608

Key Eligibility Criteria

  • Histologically- or cytologically-documented NSCLC presenting with locally-advanced, unresectable stage III disease (Version 8 of AJCC Staging Manua…
  • For stage III or recurrent disease, must have completed platinum-based chemotherapy and radiation therapy to all known tumor sites (60 Gy +/- 10%).…
  • Must be receiving consolidation durvalumab following completion of radiation and chemotherapy, and less than 32 weeks has elapsed from their first …
  • Able to potentially receive further consolidation chemotherapy plus durvalumab and tremelimumab, but not be currently intended to receive additiona…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →